Description
Quantity: 250 mL
Unit Size: Each
CaptureSelect KappaXP matrix recognizes the kappa light chain of human antibodies, enabling purification of all kappa-containing Ig's, Fab, and Fab2 fragments directly from complex sources and feed streams.CaptureSelect KappaXP Affinity Matrix features include:
• Purification of kappa monoclonal antibodies, Fab, and Fab2 fragments directly from complex source materials in a single step with high purity and yield
• Mild elution for Fab fragments and antibodies
• Human specific, no binding to bovine antibodies
• Excellent scalability
• Excellent pH stability up to 100 mM NaOH for limited exposure
• Non–animal-derivedThe high selectivity and high yields obtained using CaptureSelect KappaXP Affinity Matrix enable a robust and efficient purification process with excellent purity in one step.Free of animal componentsCaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (VHH) created by a proprietary technology. The VHH affinity ligand is a 12 to 15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (Animal Origin-Free).Main characteristics:
• Matrix:agarose-based
• Average particle size:65 ± 10 μm
• Ligand:CaptureSelect KappaXP affinity ligand
• Ligand coupling method:epoxide immobilization of the ligand
• Fab binding capacity:20–30 g IgG Kappa-Fab/liter resin depending on flow rate, column height, and residence time
• IgG binding capacity:35–45 g IgG/liter resin depending on flow rate, column height, and residence time
• Elution conditions:20 mM citric acid or acetic acid, pH 3–4; 100 mM Tris, 1.5 M MgCl_2, pH 6
• Flow characteristics:150–300 cm/h (up to 2 bar)
• Formulation buffer:20% (v/v) ethanol
